SCHEMBL7541533

SCHEMBL7541533

COc1ccc(NS(=O)(=O)c2c(F)c(F)c(OC(=O)C(F)(F)F)c(F)c2F)cc1O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.41
LMNA P02545 7/20 0.40
MEN1 O00255 5/20 0.40
KMT2A Q03164 5/20 0.40
HTT P42858 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
ALOX15 P16050 2/20 0.40
MAPK1 P28482 2/20 0.40
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
ALDH1A1 P00352 3/20 0.39
PKM P14618 2/20 0.39
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39
TUBA1B P68363 1/20 0.39
TUBA4A P68366 1/20 0.39
TUBB4B P68371 1/20 0.39
TUBB3 Q13509 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7535753 0.90 LMNA (0.44) LMNAMEN1KMT2AHTTSMN1; SMN2
SCHEMBL6675686 0.86 LMNA (0.44) L3MBTL1LMNAMEN1KMT2AHTT
SCHEMBL6089371 0.86 CA1 (0.50) L3MBTL1LMNAMEN1KMT2AHTT
SCHEMBL6086613 0.84 CA1 (0.49) L3MBTL1LMNAMEN1KMT2AHTT
SCHEMBL6088076 0.84 CA1 (0.49) L3MBTL1LMNAMEN1KMT2AHTT
SCHEMBL7533381 0.82 ALDH1A1 (0.48) LMNASMN1; SMN2MAPK1ALDH1A1CA1
Batabulin SCHEMBL7103854 0.81 LMNA (0.48) L3MBTL1LMNAMEN1KMT2AHTT
SCHEMBL6675555 0.81 LMNA (0.48) L3MBTL1LMNAMEN1KMT2AHTT
SCHEMBL6681264 0.81 HTR6 (0.47) L3MBTL1LMNAMEN1KMT2AHTT
SCHEMBL7540113 0.81 L3MBTL1 (0.42) L3MBTL1LMNAMEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents AMGEN INC. 2002-01-31 US claimed
EP-1005453-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK, INC. (US) 2000-06-07 EP claimed
WO-1999010320-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK INC. (US) 1999-03-04 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents CYP46A1, TGFB1, NR1H2 L3MBTL1 1938/4885LMNA 2006/4885MEN1 2231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.